CoChat

Current Treatment for Multiple Myeloma

Avigan, David, Rosenblatt, Jacalyn · 2014 · New England Journal of Medicine
Cited by 26

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

In the past decade, we have witnessed dramatic changes in the treatment of multiple myeloma. Proteasome inhibitors such as bortezomib and carfilzomib target the ubiquitin pathway, resulting in cytotoxic injury due to disruption of protein degradation in myeloma cells. The immunomodulatory agents thalidomide, lenalidomide, and pomalidomide target myeloma cells through several mechanisms including direct cytotoxicity, antiangiogenic effects, and activation of antitumor immunity. Initial studies both with proteasome inhibitors and with immunomodulatory drugs in patients with relapsed or refractory disease have shown highly encouraging results.1,2 In patients 65 years of age or younger, high-dose chemotherapy with autologous stem-cell transplantation has . . .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejme1407442

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 26

Metadata

Authors
Avigan, D., & Rosenblatt, J.
Venue
New England Journal of Medicine
Published
2014-09-04
Volume
371
Issue
10
Pages
961-962
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1976486305
Cited by
26
References
7
FWCI
2.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current Treatment for Multiple Myeloma. https://app.cochat.ai/papers/10.1056/nejme1407442
The paper
Avigan, D., & Rosenblatt, J. (2014). Current Treatment for Multiple Myeloma. New England Journal of Medicine. https://doi.org/10.1056/nejme1407442

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.